sellWeak cluster of 610b5-1 plan
Catriona Yale sold $264k of AKRO
Chief Development Officer at Akero Therapeutics, Inc.. 9,074 shares at an average of $29.11, traded Dec 16, 2024, filed Dec 18, 2024.
Warning score
8Value
$264k
9,074 shares
Holdings after
95,648
-9% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +13Trade size$264k at market
- 0Share of holdings soldSold 8.7% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-138146, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2024 | AGrant or award Common Stock10b5-1 | +24,300 | $0.00 | $0 | 95,648 | Dec 18, 2024 |
| Dec 16, 2024 | MOption exercise Common Stock10b5-1 | +9,074 | $21.10 | $191k | 104,722 | Dec 18, 2024 |
| Dec 16, 2024 | SOpen-market sale Common Stock10b5-1 | -9,074 | $29.11 | $264k | 95,648 | Dec 18, 2024 |
| Dec 16, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,074 | $0.00 | $0 | 20,000 | Dec 18, 2024 |
| Dec 16, 2024 | AGrant or award Stock Option (Right to Buy)derivative10b5-1 | +73,700 | $0.00 | $0 | 73,700 | Dec 18, 2024 |
Related signals
Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 5Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $108k 2,000 shares | -6% | |
| 14Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $542k 10,000 shares | -10% | |
| 44Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $80k 1,453 shares | -1% | |
| 39Weak | Akero Therapeutics, Inc. | Catriona Yale Chief Development Officer | $90k 1,633 shares | -2% | |
| 46Moderate | Akero Therapeutics, Inc. | William Richard White Chief Financial Officer | $90k 1,634 shares | -3% | |
| 37Weak | Akero Therapeutics, Inc. | Timothy Rolph Chief Scientific Officer | $62k 1,129 shares | -1% | |
| 37Weak | Akero Therapeutics, Inc. | Patrick Lamy Senior VP, Commercial Strategy | $48k 875 shares | -3% | |
| 36Weak | Akero Therapeutics, Inc. | Scott A. Gangloff Chief Technology Officer | $47k 848 shares | -3% | |
| 55Moderate | Akero Therapeutics, Inc. | Andrew Cheng President and CEO | $363k 6,620 shares | -1% | |
| 46Moderate | Akero Therapeutics, Inc. | Jonathan Young Chief Operating Officer | $135k 2,493 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.